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RESEARCH NOTE
Summary. The susceptibility of mobile and cystic forms of Borrelia burgdorferi
to tinidazole (TZ) was examined. The minimal bactericidal concentration (MBC)
of TZ against the mobile spirochetes was >128 µg/ml at 37°C in micro-oxic atmos-
phere when incubated for 14 days. TZ significantly reduced the conversion of
mobile spirochetes to cystic forms during incubation. The MBC for older (10-
months-old) cysts at 37°C in a micro-oxic atmosphere was >0.5 µg/ml, but
>0.125µg/ml for young (1-day-old) cysts. Acridine orange staining, dark-field
microscopy and transmission electron microscopy revealed that, when the concen-
tration of TZ was ≥ MBC, the contents of the cysts were partly degraded, core
structures did not develop inside the young cysts, and the amount of RNA in these
cysts decreased significantly. When cysts were exposed to TZ, both the spirochetal
structures and core structures inside the cysts dissolved, and the production of
blebs was significantly reduced. These observations may be valuable in the treat-
ment of resistant infections caused by B. burgdorferi, and suggest that a combina-
tion of TZ and a macrolide antibiotic could eradicate both cystic and mobile forms
of B. burgdorferi. [Int Microbiol 2004; 7(2):139–142]
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Introduction
Borrelia afzelii, B. garinii, and B. burgdorferi, the causative
agents of Lyme borreliosis, are able to rapidly migrate away
from the initial point of infection [19], and may cause long-
term tissue infections frequently leading to a chronic disease
course. Lyme borreliosis can infect several organs, but the
hallmark of this disease is the expanding red rash with central
clearing, called erythema migrans. Unfortunately, many
Borrelia-affected persons will not develop this typical rash. In
a recent study, all erythemas associated with Borrelia garinii
were rapidly forming, and they were large and homogeneous.
This was in contrast to erythemas associated with B. afzelii,
which were generated slowly, small and predominantly annu-
lar [11]. Therefore, infections with B. afzelii may be treated
too late, which contributes to severe late manifestations.
Fourteen days of treatment with penicillin, doxycyclin or
ceftriaxone is often believed to cure the infection, but all
commonly used antibiotics have their shortcomings, and the
frequency of relapses may be highly dependent on the chosen
treatment and the phase of the disease [23−26]. A study of
cytomorphic variations of B. burgdorferi isolates from
patients with or without antibiotic treatment showed that
penicillin can induce membrane-derived vesicles (cysts or
spheroblast L-forms) in vivo [27]. This conversion of mobile
Borrelia to cystic forms was subsequently observed for cef-
triaxone, doxycyclin [17], ciprofloxacin [18] and vancomy-
cin [12] at concentrations achievable in vivo. The fact that B.
burgdorferi has the ability to convert (and reconvert) to cys-
tic forms both in vivo and in vitro [1,4−6,10,14,15,21,27,28]
may be regarded as an explanation why the infection may be
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persistent and reactivate. Therefore, it is reasonable to sug-
gest that all germinative forms of the bacterium (and not only
the motile form) should be destroyed so that Lyme borrelio-
sis can be treated effectively. The aim of this study was to
investigate the susceptibility of motile and cystic forms of B.
burgdorferi to the second-generation amidazole tinidazole.
Materials and methods
The bacterial strain used in the experiments was B. burgdorferi ACA-1.
Spirochetes and cystic forms were produced as previously described [8].
Susceptibility testing with tinidazole. Fasigyn (tinidazole, TZ) 500 mg
(Pfizer Ltd., Sandwich, England) was dissolved in distilled water, sterile fil-
tered through a 0.2-µm filter, and diluted geometrically in 5-ml Nalgene
tubes at concentrations ranging from 512 to 0.06 µg/ml in 2 ml diluted BSK-
H medium (dilution 1:100 in distilled water). The control consisted of a tube
containing only diluted BSK-H. A 2-ml suspension of cystic forms at the age
of 24 h and 10 months was added to each of the TZ dilutions and to the con-
trol tube in a final concentration of 256 to 0.03 µg/ml.
Susceptibility to TZ was tested for mobile spirochetes in a final dilution
of 512–0.03 µg/ml in non-diluted BSK-H medium. The final volume was 4 ml
in each tube; to which 40 µl of exponentially growing bacteria (107 cells) were
added. To examine whether TZ prevented the conversion of normal mobile
spirochetes to cystic forms, susceptibility was also tested in distilled water. 
Incubation conditions for susceptibility testing. The susceptibility of 1-day-
old and 10-month-old cysts was tested. The 1-day-old cysts were incubated
under oxic and micro-oxic conditions at 30°C for 2 weeks, and additionally at
37°C in a micro-oxic atmosphere. Older cysts in distilled water and motile
bacteria in BSK-H medium were incubated at 37°C. Motile bacteria in dis-
tilled water were incubated under micro-oxic conditions at 30°C for 14 days.
Examination of the tinidazole-exposed microbes. The tinidazole-exposed
microbes were examined as reported earlier for hydroxychloroquine-
exposed microbes [8] with one exception: vital staining was done on TZ-
exposed cysts at 30°C and 37°C by mixing 10 µl of Live/dead BacLight
bacterial viability kit (Molecular Probes L-13152 Eugene, Oregon USA) and
10 µl of culture on a glass slide protected with a cover-slip, followed by
incubation in the dark for 15 min. The vitally stained cysts were examined
by UV-microscopy (400–2000×). 
Reconversion of cystic forms to spirochetal forms. A 0.3-ml sample of
each TZ dilution in distilled water (106 cysts/ml) was transferred to 4 ml
BSK-H medium (resulting in 8 × 104 cysts/ml). The samples were incubated
at 30°C with tight caps as previously described [8]. 
Examination by electron microscopy. The following cultures were exam-
ined by transmission electron microscopy (TEM): young cysts from TZ-free
controls and from cultures with 0.5 and 32 µg TZ/ml in distilled water incu-
bated at 37°C for 14 days micro-oxically, and control cysts incubated in
BSK-H medium for 14 days. TEM was done as described earlier [9].
Results and Discussion
In 1999, we published a study on the treatment of cystic forms
of B. burgdorferi with metronidazole (MZ) [7]. However, this
drug may not be tolerated by all patients. Therefore, the sec-
ond generation 5-nitroimidazole tinidazole, which is better
tolerated by most patients and may also be more efficient than
MZ [13] was tested. Susceptibility testing of normal mobile
Borrelia showed that the MBC to TZ was >128 µg/ml in cul-
tures incubated at 37°C for 14 days in a micro-oxic atmos-
phere. This shows that TZ is effective against mobile spiro-
chetes but that normal doses and short courses of treatment
probably do not kill the bacteria. The addition to motile spiro-
chetes of distilled water with a TZ concentration achievable in
vivo restrained the formation of cysts. Rupturing was
observed in about 10–90% of the cysts that had been incubat-
ed in TZ-dilutions of 0.5–512 µg/ml at 37°C for 14 days under
micro-oxic conditions. Other antibiotics act oppositely, by
stimulating the appearance of cystic forms [12,17,18,27]. In
acridine-orange-stained fixed smears of cysts, the control
cysts (not TZ-exposed) were bright orange-red (indicating
abundant amounts of RNA inside the cysts and suggesting
intense biological activity, whereas inactive cysts are green).
These cysts contained distinct spirochetal and core structures.
When incubated for 2 weeks, 40–50% of the 10-month-old
cysts and 10–20% of the 1-day-old cysts contained core struc-
tures. When incubated micro-oxically at 37°C with TZ con-
centrations of 0.125 µg/ml (1-day-old cysts) and 0.5 µg/ml
(10-month-old cysts), less than 5% of the cysts contained core
structures; instead, the cysts had dissolved, revealing their
green contents. For 1-day-old cysts incubated at 30°C, the
MBC limit was 16 µg/ml (oxically) and 1 µg/ml (micro-oxi-
cally). TEM and acridine-orange staining revealed disruption
of the cysts when the TZ concentration was higher than or
equal to the above-mentioned values. TEM showed that 
the content of the cysts dissolved completely when the con-
centration of TZ was 32 µg/ml and the samples had been
incubated at 37°C for 14 days in a micro-oxic atmosphere
(Fig. 1).
The reduced ability of TZ to pass through the cell mem-
brane when oxygen is present may account for the observed
differences in the development and appearance of the cysts
with respect to the presence or absence of oxygen during the
incubation. We hypothesize that anoxic conditions can be
achieved inside the cysts during micro-oxic incubation. This
may result in a higher influx of TZ, and under anoxic condi-
tions reduced metabolites of TZ that interact directly with
DNA. For cysts incubated micro-oxically at 37°C for 14
days, viable/dead staining with BacLight™ revealed bright
green cores and spirochetes for TZ ≤ 0.5µg/ml (old cysts) and
TZ ≤ 0.125µg/ml (young cysts); above these limits, the cysts
were red. Young cysts (1-day-old) incubated at 30°C under
the same conditions appeared green for TZ ≤ 8µg/ml and red
for TZ > 8µg/ml. Some large cysts (5 µm) harbored multiple
spirochetal forms, which suggests that binary fission had
taken place inside the cysts (Fig. 2).
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When control cysts—or cysts that had been exposed to a
low concentration of TZ—were transferred to BSK-H medi-
um, about 10–20% of the cysts converted to immobile spiro-
chetes, as happens in response to low concentrations of
hydroxychloroquine [8]. The converted spirochetes were rel-
atively short and thin, but a few (1–5%) were of normal
length. No further development was observed beyond a 1-month
incubation. At TZ concentration above MBC, no beginning
spirochetes were seen protruding from the cysts, and the
structure of the cysts was disrupted. The conversion into
immobile spirochetes in BSK-H medium was consistent with
the results of several other experiments using the same con-
centrations of TZ: (i) a low number of orange acridine-
orange-stained structures [22], (ii) an intense green color of
cells stained with vital BacLight™ [2] and (iii) a non-disrupted
intracystal ultrastructure (TEM). When the cysts were incu-
bated with a high concentration of TZ (32 µg/ml), no blebs
originated. In contrast, incubation with MZ produced a few
blebs [7]. Therefore, TZ may have more adverse effects on
the DNA in the blebs than MZ. As the content of the blebs is
of great pathogenic importance, TZ may be better suited for
the treatment of Lyme disease [20].
Our results show that TZ as a single agent is not sufficient
to treat Borrelia infections because mobile spirochetes are
highly resistant to this agent. However, TZ has the ability to
inhibit the development of cystic forms and to disrupt spiro-
chetes and core structures inside the cysts at concentrations
achievable in vivo by the administration of a single 1.5-g
dose [3]. This supports testing the hypothesis that TZ pre-
vents persistent infections in vivo, as suggested by the obser-
vation of similarities between the aerobic Mycobacterium
tuberculosis and B. burgdorferi: In its coccoid form (L-form),
M. tuberculosis is anaerobic and sensitive to metronidazole
[30]. In addition, tinidazole is also an effective eradicator of
Clostridium difficile and may prevent yeast infection [29],
which may be troublesome during long-term treatment of
Lyme disease. Another advantage of TZ compared to MZ is
its higher accumulation in the cerebrospinal fluid [16]. Dual
medication with TZ and a macrolide (clarithromycin,
azithromycin or the new ketolide telithromycin) might be an
interesting approach to treat borrelioses, and to prevent per-
sistent infections.
References
1. Alban PS, Johnson PW, Nelson DR (2000) Serum-starvation-induced
changes in protein synthesis and morphology of Borrelia burgdorferi.
Microbiology 146:119–127
2. Alonso JL, Mascellaro S, Moreno Y, Ferrús MA, Hernández J (2002)
Double-staining method for differentiation of morphological changes
and membrane integrity of Campylobacter coli cells. Appl Environ
Microb 68:5151–5154 
3. Bergan T, Solhaug JH, Soreide O, Leinebo O (1985) Comparative phar-
macokinetics of metronidazole and tinidazole and their tissue penetra-
tion. Scan J Gastroenterol 8:945–950
4. Brorson Ø, Brorson SH (1997) Transformation of cystic forms of
Borrelia burgdorferi to normal mobile spirochetes. Infection 25:240–246
5. Brorson Ø, Brorson SH (1998) In vitro conversion of Borrelia burgdor-
feri to cystic forms in spinal fluid, and transformation to mobile spiro-
chetes by incubation in BSK-H medium. Infection 26:144–150
TINIDAZOLE AGAINST B. BURGDORFERI
In
t. 
M
ic
ro
bi
ol
.
In
t. 
M
ic
ro
bi
ol
.
Fig. 2. One-day old cystic forms in distilled water without tinidazole, incu-
bated microoxically at 37°C for 14 days. The cysts (a, b) were vitally stained
with BacLight™. Core structures are observed inside some cysts. A large
cyst (5 µm) in which binary fission of spirochetes has occurred is present.
The cyst itself is also in a fission process. Bar: 1 µm.
Fig. 1. Susceptibility testing of 1-day-old cystic forms of Borrelia burgdor-
feri in distilled water. The cysts were exposed to a tinidazole concentration
of 32 µg/ml and incubated micro-oxically at 37°C for 14 days. The content
of the cysts is almost completely degraded and their envelopes are disrupt-
ed.  (white circle). No blebs can be seen. Bar: 500 nm.
Estudio in vitro de la susceptibilidad de las formas
móviles y císticas de Borrelia burgdorferi al tinidazol
Resumen. Este estudio examina la susceptibilidad al tinidazol (TZ) de las
formas móviles y císticas de Borrelia burgdorferi. La concentración bacteri-
cida mínima (CBM) de TZ para las espiroquetas móviles era >128 µg/ml a
37°C en atmosfera microóxica e incubación durante 14 días. El TZ redujo
significativamente la conversión de espiroquetas móviles a la forma cística
durante la incubación. La CBM para los cistos viejos (de 10 meses) a 37°C
y en atmosfera microóxica era >0.5 µg/ml, mientras para los cistos jóvenes
(de un día) era >0.125 µg/ml. La tinción con naranja de acridina, la micro-
scopia de campo oscuro, y la microscopia electrónica de transmisión
mostraron que cuando la concentración de TZ era ≥MBC el contenido de los
cistos se degradaba parcialmente, no se desarrollaban las estructuras
nucleares en el interior de los cistos jóvenes, y la cantidad de RNA en dichos
cistos disminuía significativamente. Cuando los cistos se exponían a TZ, las
estructuras espiroquetales y nucleares de su interior se disolvían, y la produc-
ción de vesículas se reducía significativamente. Estas observaciones pueden
ser importantes en el tratamiento de infecciones resistentes causadas por B.
burgdorferi, y sugieren que la combinación de TZ con un antibiótico macróli-
do podría erradicar tanto las formas císticas de B. burgdorferi como las móvi-
les. [Int Microbiol 2004; 7(2):139–142]
Palabras clave: Borrelia burgdorferi · formas císticas · espiroquetas ·
esferoplasto · tinidazol
Estudo in vitro da susceptibilidade das formas móveis e
císticas de Borrelia burgdorferi ao tinidazol
Resumo. Este estudo examina a susceptibilidade das formas móveis e cís-
ticas de Borrelia burgdorferi ao tinidazol (TZ). A mínima concentração bac-
tericida (MCB) de TZ para as espiroquetas móveis foi >128 mg/ml a 37°C
em atmosfera microóxica e incubação durante 14 dias. O TZ reduziu signi-
ficantemente a conversão das espiroquetas móveis à forma cística, durante a
incubação. A CBM para os cistos velhos (de 10 meses) a 37°C e em atmos-
fera microóxica era >0,5 mg/ml, enquanto que para os cistos jovens (de um
dia) era >0,125 mg/ml. A coloração com acridina laranja, a microscopia de
campo escuro e a microscopia eletrônica de transmissão mostraram que
quando a concentração de TZ era ≥CBM o conteúdo dos cistos se degrada-
va parcialmente, não se desenvolviam as estruturas nucleares no interior dos
cistos jovens e a sua quantidade de RNA diminuía significantemente.
Quando os cistos se expunham a TZ, as estruturas espiroquetais e as nuclear-
es de seu interior se dissolviam e a produção de vesículas se reduzia signi-
ficantemente. Estas observações podem ser importantes no tratamento de
infecções resistentes causadas por B. burgdorferi e sugerem que a combi-
nação de TZ com um antibiótico macrólido poderia erradicar tanto as formas
císticas de B. burgdorferi como as móveis. [Int Microbiol 2004; 7(2):
139–142]
Palavras chave: Borrelia burgdorferi · formas císticas · espiroquetas ·
esferoplasto · tinidazol
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